Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick S Parfrey

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
American Journal of Nephrology|May 27, 2010
Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?Patrick S Parfrey
Annals of Internal Medicine|November 7, 2007
Inhibitors of the renin angiotensin system: proven benefits, unproven safetyPatrick S Parfrey
Kidney International|March 23, 2005
Autosomal-recessive polycystic kidney diseasePatrick S Parfrey
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 27, 2005
Target hemoglobin level for EPO therapy in CKDPatrick S Parfrey
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 6, 2007
In the literature: on clinical performance measures and outcomes among hemodialysis patientsPatrick S Parfrey
Annals of Internal Medicine|July 8, 2009
Angiotensin-receptor blockers in the prevention or treatment of microalbuminuriaPatrick S Parfrey
Seminars in Dialysis|March 19, 2003
The clinical epidemiology of cardiovascular disease in chronic kidney diseasePatrick S Parfrey
Seminars in Dialysis|September 13, 2011
Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsivenessPatrick S Parfrey
Current Opinion in Nephrology and Hypertension|December 16, 2010
Critical appraisal of randomized controlled trials of anemia correction in patients with renal failurePatrick S Parfrey
Clinical Journal of the American Society of Nephrology : CJASN|May 29, 2010
BNP in hemodialysis patientsPatrick S Parfrey
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
American Journal of Nephrology|May 27, 2010
Editorial perspective. Should hemoglobin targets for anemic patients with chronic kidney disease be changed?Patrick S Parfrey
Annals of Internal Medicine|November 7, 2007
Inhibitors of the renin angiotensin system: proven benefits, unproven safetyPatrick S Parfrey
Kidney International|March 23, 2005
Autosomal-recessive polycystic kidney diseasePatrick S Parfrey
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 27, 2005
Target hemoglobin level for EPO therapy in CKDPatrick S Parfrey
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 6, 2007
In the literature: on clinical performance measures and outcomes among hemodialysis patientsPatrick S Parfrey
Annals of Internal Medicine|July 8, 2009
Angiotensin-receptor blockers in the prevention or treatment of microalbuminuriaPatrick S Parfrey
Seminars in Dialysis|March 19, 2003
The clinical epidemiology of cardiovascular disease in chronic kidney diseasePatrick S Parfrey
Seminars in Dialysis|September 13, 2011
Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsivenessPatrick S Parfrey
Current Opinion in Nephrology and Hypertension|December 16, 2010
Critical appraisal of randomized controlled trials of anemia correction in patients with renal failurePatrick S Parfrey
Clinical Journal of the American Society of Nephrology : CJASN|May 29, 2010
BNP in hemodialysis patientsPatrick S Parfrey
Pageof 16